Esperion Therapeutics Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (33)

View All

Latest Posts

About This Stock More About This Stock
Abbvie Earnings Drive Biotech Stocks Higher With Large Caps Dominant
Article By: Rod Raynovich
Friday, January 26, 2018 6:44 PM EST
Biotech stocks soared again today to new highs driven by Abbvie Inc. earnings and overall sector strength. Momentum was strong in the general market with NASDAQ up 1.28% and the S&P up 1.18%. The M&A theme should be the driver in 2017.
In this article: IBB, REGN, BIIB, NBIX, XBI, ICPT, ESPR, ABBV, PTLA
Read
3 Of The Best & Worst Performing Drug Stocks Of Q1
Article By: Arpita Dutt
Thursday, April 6, 2017 11:37 AM EST
Pharma and biotech stocks have been showing signs of recovery this year. The sector started the year on a strong note with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 10.7% and 5.7%, in the first quarter of 2017.
In this article: ESPR, VRTX, NKTR, ARGS, CDTX, XENE
Read
Ruling By FDA Causes Shares Of Esperion Therapeutics, Inc. To Jump 50% Today
Article By: Lorimer Wilson
Monday, March 20, 2017 3:23 PM EST
Esperion announced this morning that the FDA is willing to sign off on an approval for its lead drug - provided it clears LDL lowering goals in a pivotal study - without a cardio study as a prerequisite. Its shares soared more than 50% on the news.
In this article: AMGN, ESPR
Read
Cholesterol Stocks Clobbered: Good Clinical Results But High Expectations
Article By: Rod Raynovich
Friday, March 17, 2017 10:17 AM EST
Results from a long-term study on the efficacy of a new generation of LDL cholesterol reducing drugs fell short of expectations and clobbered four stocks: AMGN, ESPR, MDCO and REGN.
In this article: AMGN, REGN, MDCO, ESPR Also: IBB, XBI, XLV
Read
Healthcare Stocks Lead On A Lackluster Day
Article By: Rod Raynovich
Monday, April 4, 2016 8:30 PM EST
Lagging healthcare and biotech stocks found buyers today. The healthcare SPDR ETF was up 1.05% to $69.38 as investors were probably seeking dividends and safety with fears about pricing tempered.
In this article: BMY, EW, RHHBY, ACAD, ALNY, ALXN, ANAC, IBB, GILD, NBIX, VRTX, ZIOP, XBI, XLV, ESPR, ABBV, KITE, BLUE, EDIT
Read
All Posts

PARTNER HEADLINES

Latest Tweets for $ESPR

No tweets yet!